BioDuro and Cenra API Solutions forge global API manufacturing joint venture in Taiwan

The Taipei facility boasts 10 GMP API production lines, with a total reactor volume exceeding 350,000 liters

BioNTech co-founders launch new mRNA venture, aiming to revolutionize next-gen therapies

The new entity will operate with separate resources, funding, and operations, while BioNTech will contribute related rights and mRNA technologies to support its ambitious mission

GelMEDIX partners with Catalent to advance vision-restoring cell therapies

The biotechnology company will tap into Catalent’s expertise in induced pluripotent stem cells and advanced cell-therapy manufacturing

Co-Diagnostics bags key Japanese patent, bolstering global push for rapid PCR testing

The Japan Patent Office is considered one of the world's most rigorous and meticulous in its review process

FDA okays JUXTAPID for kids with ultra-rare genetic cholesterol disorder

Rapid medical weight loss fuels surge in facial aesthetics, Allergan data shows

Recent data reveal that patients undergoing MWL are entering aesthetic practices with unique needs tied to facial structure and skin quality

DKSH Malaysia teams up with Pfizer to boost access to anti-infective therapies

Pfizer’s anti-infectives portfolio includes both established therapies for moderate to severe infections and newer, clinically robust antimicrobial treatments

Wanbury unveils API facility in Tanuku, targets Rs. 100 crore revenue

The Tanuku facility will focus on the production of key therapeutic APIs, including Anti-Tussive, Anti-Coagulant (Blood Thinner), Anaesthetic, and Antidepressant molecules

Bayer and Vanderbilt launch five-year partnership to accelerate innovative therapies

The partnership initially will focus on cardiovascular and kidney diseases

Sigachi Industries achieves key R&D milestone in Cystic Fibrosis APIs

The development marks an important step in Sigachi's strategic focus on expanding its presence in complex, high-value specialty APIs, aligned with global demand for advanced therapies in rare and chronic disease segments